Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AIM-IBD: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of a Microbiome-Targeted Food Supplement Versus Placebo in Adults With Mild-to-Moderate, Objectively Active Ulcerative Colitis

NCT07619638 is registered in ClinicalTrials.gov with ENBIOSIS BIOTECHNOLOGIES as lead sponsor.

NCT NCT07619638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07619638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AIM-IBD: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of a Microbiome-Targeted Food Supplement Versus Placebo in Adults With Mild-to-Moderate, Objectively Active Ulcerative Colitis
Lead sponsor
ENBIOSIS BIOTECHNOLOGIES
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 10, 2026
Completion date
April 30, 2028
Enrollment
162 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, inflammatory bowel disease (ibd), ulcerative colitis (uc)